P105 NEX-T CD19 chimeric antigen receptor (CAR) T-cell therapy CC-97540 (BMS-986353): Preclinical and translational evidence of deep B-cell depletion suitable for study in severe refractory autoimmune diseases
Georg Schett(Karolinska University Hospital), Amitkumar Mehta(University of Alabama at Birmingham), Tatyana Feldman(Hackensack University Medical Center), Boyu Hu(University of Utah), Jerill Thorpe(Bristol-Myers Squibb (United States)), Ashley K. Koegel(Bristol-Myers Squibb (United States)), Alison Maier(Bristol-Myers Squibb (United States)), Nikolay Delev(Bristol-Myers Squibb (Sweden)), Matthew Westoby(Bristol-Myers Squibb (United States)), David Kugler(Bristol-Myers Squibb (United States)), Divya Varun(Bristol-Myers Squibb (United States)), Fan Wu(Anhui Medical University), Jeremy S. Abramson(Massachusetts General Hospital), Fabien Müller(Friedrich-Alexander-Universität Erlangen-Nürnberg), Ruth A. Salmon(Bristol-Myers Squibb (United States))
Cited by 2
Related Papers
Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin
|Journal of Clinical Investigation|2012|708
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580
EULAR definition of difficult-to-treat rheumatoid arthritis
|Annals of the Rheumatic Diseases|2020|538